KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Operating Leases (2018 - 2025)

Vertex Pharmaceuticals (VRTX) has 8 years of Operating Leases data on record, last reported at $1.5 billion in Q2 2025.

  • For Q2 2025, Operating Leases rose 160.29% year-over-year to $1.5 billion; the TTM value through Jun 2025 reached $1.5 billion, up 160.29%, while the annual FY2024 figure was $1.5 billion, 304.61% up from the prior year.
  • Operating Leases reached $1.5 billion in Q2 2025 per VRTX's latest filing, down from $1.5 billion in the prior quarter.
  • Across five years, Operating Leases topped out at $1.7 billion in Q3 2024 and bottomed at $354.4 million in Q3 2023.
  • Average Operating Leases over 5 years is $648.0 million, with a median of $377.2 million recorded in 2021.
  • Peak YoY movement for Operating Leases: decreased 7.3% in 2023, then surged 366.99% in 2024.
  • A 5-year view of Operating Leases shows it stood at $377.4 million in 2021, then increased by 0.56% to $379.5 million in 2022, then grew by 0.58% to $381.7 million in 2023, then soared by 304.61% to $1.5 billion in 2024, then decreased by 1.1% to $1.5 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $1.5 billion in Q2 2025, $1.5 billion in Q1 2025, and $1.5 billion in Q4 2024.